Chronic Lymphocytic Leukemia Clinical Trials in Providence, Rhode Island

4 studies are recruiting for chronic lymphocytic leukemia in Providence, Rhode Island right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

  1. Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)

    This is a Phase 1/1b, nonrandomized, open-label, parallel assignment, dose-escalation, and dose-expansion study to evaluate the safety and clinical activity of azer-cel, an allogeneic anti-CD19 CAR T, in adults with r/r B ALL, r/r B-cell NHL and CLL/SLL.

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Lifespan Cancer Institute at Rhode Island Hospital, Providence, Rhode Island
    Locations
    15 in total
    Run by
    Imugene Limited

    See if you can join NCT03666000 on ClinicalTrials.gov

  2. Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

    This study collects blood and tissue samples from patients with cancer and without cancer to evaluate tests for early cancer detection. Collecting and storing samples of blood and tissue from patients with and without cancer to study in the laboratory may help researchers develop tests for the earl…

    Stage
    Not phased
    Ages
    40 to 75
    Site
    Providence Veterans Administration Hospital, Providence, Rhode Island
    Locations
    745 in total
    Run by
    Alliance for Clinical Trials in Oncology

    See if you can join NCT05334069 on ClinicalTrials.gov

  3. A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)

    Chronic lymphocytic leukemia (CLL) is the most common leukemia (cancer of blood cells). The purpose of this study is to assess the safety of venetoclax in combination with obinutuzumab or acalabrutinib in the treatment of CLL. Adverse events and change in disease activity will be assessed. Venetocl…

    Stage
    Phase 3
    Ages
    18 and older
    Site
    Lifespan Cancer Institute - Providence /ID# 266550, Providence, Rhode Island
    Locations
    70 in total
    Run by
    AbbVie

    See if you can join NCT06428019 on ClinicalTrials.gov

  4. Study of SGR-1505 in Mature B-Cell Neoplasms

    The purpose of this study is to evaluate safety and tolerability and to determine the maximum tolerated dose (MTD) or maximum administered dose (MAD) and/or recommended dose (RD) of SGR-1505.

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Rhode Island Hospital, Providence, Rhode Island
    Locations
    36 in total
    Run by
    Schrödinger, Inc.

    See if you can join NCT05544019 on ClinicalTrials.gov

How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.

What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.

Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.